Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

Deborah A. Bowen, Timothy G. Call, Greg D. Jenkins, Clive S Zent, Susan M. Schwager, Daniel L. Van Dyke, Diane F. Jelinek, Neil E. Kay, Tait D. Shanafelt

Research output: Contribution to journalArticle

86 Scopus citations

Abstract

Chronic lymphocytic leukemia (CLL) patients with aggressive molecular characteristics such as deletion of 17p13.1 do not respond to conventional treatments and have a shorter survival. Studies suggest that high-dose methylprednisolone (HDMP) has activity in such patients and combining HDMP with rituximab may enhance efficacy. We identified 37 patients with CLL treated with the HDMP-rituximab who had follow-up at Mayo Clinic. Nine of 27 (33%) had deletion of 17p13.1 and six of 27 (22%) had deletion of 11q22.3. After a median of one cycle of HDMP-rituximab, 29 (78%) patients had an objective response according to the National Cancer Institute CLL Working Group Criteria including five of nine patients with deletion of 17p13.1. Eight (22%) patients had a complete clinical response. Although well tolerated, 11 (29%) patients developed infectious complications before completing one month of therapy. Three-year survival was 41% (95% CI: 26-66%). HDMP-rituximab is an active regimen in patients with relapsed, refractory, and cytogenetically high-risk CLL. Further evaluation of this regimen in controlled trials appears warranted.

Original languageEnglish (US)
Pages (from-to)2412-2417
Number of pages6
JournalLeukemia and Lymphoma
Volume48
Issue number12
DOIs
StatePublished - Dec 1 2007

Keywords

  • 17P-
  • CLL
  • Methylprednisolone
  • Rituximab
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features'. Together they form a unique fingerprint.

Cite this